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aThe inﬂuence of patient and wound variables
on healing of venous leg ulcers in a randomized
controlled trial of growth-arrested allogeneic
keratinocytes and ﬁbroblasts
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Yuxin Zhang, PhD,e Tommy D. Lee, MSHS,f D. Innes Cargill, PhD,f and Herbert B. Slade, MD,f,g
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Objective: To examine patient and wound variables presumed to inﬂuence healing outcomes in the context of therapeutic
trials for chronic venous leg ulcers.
Methods: This double-blind, vehicle-controlled study was conducted with randomized assignment to one of four cell
therapy dose groups (n[ 46, 43, 44, 45) or vehicle control (n[ 50). A 2-week run-in period was used to exclude rapid
healers and those with infection or uncontrolled edema. This was a multicenter (ambulatory, private, hospital-based and
university-based practices, and wound care centers in North America) study. Adults $18 years old with chronic venous
insufﬁciency associated with an uninfected venous leg ulcer (2-12 cm2 area, 6-104 weeks’ duration) were included in the
study. Excluded were pregnant or lactating women, wounds with exposed muscle, tendon or bone, patients unable to
tolerate compression bandages, or patients who had exclusionary medical conditions or exposure to certain products.
Exclusion during run-in included patients with infection, uncontrolled severe edema or with healing rates $0.349 cm/2
wk. Screen fail rate was 37% (134/362), and the withdrawal rate was w10% (23 of 228). Growth-arrested neonatal
dermal ﬁbroblasts and keratinocytes were delivered via pump spray in a ﬁbrin sealant-based matrix, plus a foam dressing
and four-layer compression bandaging. Treatment continued for 12 weeks or until healed, whichever occurred ﬁrst.
Patient demographic and wound-related variables were evaluated for inﬂuence on complete wound healing in all patients,
as well as the subsets of treated and control patients.
Results:Wound duration (P[ .004) and the presence of speciﬁc quantities of certain bacterial species (P < .001) affected
healing in the vehicle group, while healing in the cell-treated groups was inﬂuenced by wound duration (P [ .012),
wound area (P[ .026), wound location (P[ .011), and speciﬁc quantities of certain bacterial species (P[ .002). Age,
sex, race, diabetes, HbA1C, peripheral neuropathy, and serum prealbumin did not signiﬁcantly affect healing. Body mass
index was positively associated with healing in cell-treated patients.
Conclusions:Wound duration is a quantiﬁable surrogate for one or more undeﬁned variables that can have a profound
negative effect on venous leg ulcer healing. Although cell therapy overcame barriers to healing, the only speciﬁc
barrier identiﬁed was the presence of certain bacterial species. Interventional trials of potentially effective new
therapies can be most informative when patients with suspected barriers to healing are included. The speciﬁc
measurement of candidate barriers such as microbial pathogens, wound inﬂammatory state, and ﬁbroblast function
should be considered in future randomized trials to improve our understanding of the basis for chronicity. (J Vasc
Surg 2013;58:433-9.)Venous leg ulcers (VLUs) do not universally heal
following standard therapies.1 Reducing reﬂux or correct-
ing obstruction may address pathologies that lead to ulcer-
ation, but such therapy failed to improve healing in
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employed, however, a considerable proportion of wounds
are relentlessly unresponsive.3
Identifying variables, which predict a poor response,
may prompt earlier consideration of appropriate advanced
therapies for certain patients.4 Variables previously identi-
ﬁed include initial wound size, wound duration, coexistent
arterial insufﬁciency, increased body mass index (BMI),
history of deep vein thrombosis (DVT), limited range of
motion at the ankle (calf pump dysfunction), and poor
compliance with compression. Recurrent DVT and poor
arterial supply are potentially modiﬁable,5-7 as are general
mobility, ankle movement, obesity, and presence of ﬁbrin
in the wound bed5,6 while patient age, sex, and history of
hip/knee replacement surgery are nonmodiﬁable variables
found by some to inﬂuence response to standard care.
The two most commonly predictive factors, ulcer size
and duration, may in fact be surrogates for potentially
unidentiﬁed underlying pathologies.5,6,8,9
A prospective randomized VLU trial evaluating a novel
allogeneic cell-based bioformulation found the therapy to
be signiﬁcantly more effective than standard care.10 A
unique feature of this nonpivotal, dose-response trial
design was that trial exclusion criteria intentionally allowed
patients to enroll who would be expected to fail standard
care, on the assumption that the inﬂuence of certain
variables on the probability of not healing would be
successfully modiﬁed by the investigational new therapy.11
We report here an analysis of the impact of measured
variables on wound closure following up to 12 weeks of
cell treatment or vehicle, with both groups receiving four-
layer compression therapy. As part of the protocol design,
a 2-week run-in with standard care screened out rapid
healers and, as might be expected, factors known to inﬂu-
ence response to standard care in an unselected population
appeared less important when standard care was again
applied to those who passed the run-in. In contrast, cell
therapy achieved a greater proportion of wound closures,
and we found healing was inﬂuenced primarily by wound
duration. At least one variable, wound bioburden, was
speciﬁcally found to correlate with duration and to differen-
tially affect responses to standard care and cell therapy. Our
ﬁndings have implications for enrollment criteria in random-
ized controlled trials of potential new VLU therapies.
METHODS
Study design. HP802-247 is an investigational alloge-
neic living cell bioformulation consisting of neonatal kera-
tinocytes and ﬁbroblasts in a ﬁxed ratio of 1:9, maintained
through growth arrest using gamma irradiation.12 The
living cells are stored frozen and are rapidly thawed for
administration via a pump spray. A full description of the
study is published elsewhere.10 Brieﬂy, this multicenter
double-blind, vehicle-controlled study was conducted
using Institutional Review Board-approved protocol and
informed consent documents, with consent obtained from
all patients before screening. The primary goal was to
examine dose and frequency of application of the testmaterial for safety and efﬁcacy in reducing the size of VLU,
relative to standard care plus vehicle. Complete wound
closure, deﬁned as re-epithelialization, absence of drainage,
and lack of need for a wound dressing persisting for
2 weeks, occurred in a signiﬁcantly greater proportion
of subjects treated with cells and serves as the endpoint of
interest for this report.
Two hundred ﬁve (205) of 228 randomized patients
completed the 12-week study at 28 sites, with 23 dropouts
being attributed to adverse events (ﬁve), withdrawal of
consent (seven), disease progression (four), protocol devia-
tion (three), physician decision (one), loss to follow-up
(two), and other (one). Inclusion required duplex-
conﬁrmed venous disease and a VLU of 6-104 weeks’ dura-
tion and 2-12 cm2 area (the maximal area covered with one
spray of HP802-247) prior to debridement. Patients were
excluded for pregnancy or lactation,>3 ulcers on the target
limb, serum HbA1C > 108 mmol/mol, serum prealbumin
$150 mg/L, history of Hashimoto’s thyroiditis, nontoxic
nodular Goiter, or Grave’s disease (due to use of Cadexomer
iodine dressing during the run in phase); prior diagnosis of
systemic lupus erythematosus with elevated anti-DNA anti-
body titers; clinical impression of ulcer bed infection; docu-
mentedhistory of osteomyelitis at the targetwound location;
or refusal of or inability to tolerate compression therapy.
Patients who had successful surgical correction or
intervention aimed at improving venous return in the
target limb within 1 month preceding the screening visit
were also excluded. No limits were placed on wound bio-
burden, BMI, or peripheral neuropathy but they were
prospectively collected. The limits on counts of red and
white blood cells, platelets, glycosylated hemoglobin,
hemoglobin, and prealbumin were set generously (eg,
hemoglobin cutoff value 8.0 g/dL). The need for weekly
debridement was at the discretion of the investigator. A
run-in phase of treatment for 2 weeks with four-layer
compression and a Cadexomer iodine dressing allowed
exclusion of rapid healers. At each weekly visit, wounds
were treated by study personnel using four-layer compres-
sion bandaging plus either one of four doses of HP-802-
247 or vehicle for up to 12 weeks. No anticoagulation
therapy was required by the protocol.
Variables evaluated. Patient interviews, review of
medical records, and physical examinations were used to
determine age, sex, race, body weight and height, wound
duration and location, and history of diabetes mellitus type
I or II. BMI was calculated as weight (kg)/height2 (m).
Wound area was determined using the ARANZ Silhouette
(ARANZMedical, Ltd, Christchurch, New Zealand), which
combines a ﬁxed focal-length digital camera with dual lasers.
Computer software integral to the hand held device calcu-
lated wound area by combining laser line interpretation
with on-screen wound margin tracings. Serum was sepa-
rated from venous blood via centrifugation using serum
separator tubes, which were sent via overnight mail to North
Coast Clinical Laboratory, Inc (Sandusky, Ohio) for
measurement of prealbumin and HbA1C using standard
clinical laboratory methods. Peripheral neuropathy was
JOURNAL OF VASCULAR SURGERY
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dorsum of the foot while the patient’s gaze was averted.
Ankle goniometry was performed at baseline.
Wound bioburden was measured by quantitative bacte-
riologic culture of a 4-mm punch tissue sample taken from
the cleansed wound bed during the screening visit, prior to
run-in. Standard microbiology testing was performed by
Pathology Laboratories Inc (Toledo, Ohio), with an assay
lower limit of quantitation of 1.0  103 colony-forming
units (cfu)/g. Weekly sharp debridement was allowed but
not required. To ascertain organisms speciﬁcally associated
with impaired healing, wounds that yielded any organism at
$1.0  104 cfu/g, or >1.0  103 cfu/g for Streptococcus
agalactiae or S dysgalactiae (b-hemolytic Strep) were iden-
tiﬁed. For each genus of bacteria, the proportion of
culture-positive wounds that healed was compared against
the average healed for all cell-treated patients (60%).
Statistical analyses. Distribution of baseline character-
istics was tested using analysis of variance. Prospectively
deﬁned statistical analysis utilized a Cochran-Mantel-
Haenszel test, adjusted for pooled site, for the proportion
of subjects achieving complete wound closure by treatment
group during the 12 weeks of treatment. Missing outcomes
were imputed using the last observation carried forward.
Wound survival analysis was similarly evaluated based on
a prospective plan using Cox proportional hazard, adjusted
for baseline wound area. The Cochran-Mantel-Haenszel
test with adjustment for pooled site was used to examine
treatment effects on the number of patients who had
debridement performed at each weekly visit, performing
the test separately for each pair of an active group vs
vehicle. For the purpose of this report, post hoc analyses of
patient and wound variables were conducted using all
patients combined, patients treated with any dose of cells,
and patients treated with vehicle. Quantitative continuous
variables (wound area, wound duration, BMI, HbA1C)
were tested using parametric analysis (t-test) or, if not
normally distributed (based on the Shapiro-Wilk test), by
nonparametric analysis (Mann-Whitney rank-sum test).
Categorical variables were dichotomized as “0” or “1”
where appropriate (not healed vs healed, white vs non-
white, ankle location vs leg location, monoﬁlament
sensation no vs yes). Dichotomous categorical variables
were tested using c2 with Yates correction. Both contin-
uous and coded dichotomous variables were tested using
multiple logistic regression, using maximum likelihood
estimation. No adjustments were made for multiplicity.
The relationship between wound bioburden and median
wound duration was tested using Kruskal-Wallis one-way
analysis of variance on ranks. Prospective analyses were
performed using SAS 9.1.3 for Windows (SAS Institute
Inc, Cary, NC), with SigmaPlot 12.0 (Systat Software, Inc,
San Jose, Calif) for post hoc analyses.
RESULTS
Baseline characteristics. Demographic and wound
variables were similar among treatment groups at baseline,
with no statistical imbalances (Table I).Multivariate analysis: Age, sex, race, wound area,
wound duration, and wound location. Multivariate anal-
ysis using a multiple logistic regression model to test the
inﬂuence of age, sex, race, area, and duration on complete
wound closure found only duration to be signiﬁcant
(P < .001). Baseline wound area was a signiﬁcant single
covariate in the Cox proportional hazard analysis on
number of days to wound closure (hazard ratio, 0.914;
95% conﬁdence interval, 0.858-0.974; P ¼ .0058). A
shallow linear relationship was seen between wound dura-
tion (independent variable) and wound area (dependent
variable), but it did not reach statistical signiﬁcance (slope,
0.0124; R2 ¼ 0.0126; P ¼ .091). Increases in either
wound duration or wound area showed a negative effect
on wound closure, but wounds of any duration or area
responded better to treatment with standard care plus cells
than with standard care plus vehicle.
Wounds were nearly evenly distributed between the leg
and ankle, with slightly more located on the leg. Combining
the 228 patients across all treatment assignments, the
proportion of healed leg wounds was signiﬁcantly greater
than the proportion of healed ankle wounds (68% vs 51%;
P ¼ .018). The model was adjusted to include treatment
(cells or vehicle) and wound location, while removing age,
sex, and race. In this adjusted model, wound location (P ¼
.012), duration (P # .001), and treatment (P ¼ .004)
signiﬁcantly affected complete healing, whereas baseline
wound area did not (P ¼ .106).
Univariate analyses. Within the cell-treated group,
baseline wound area was signiﬁcantly smaller in those who
healed compared with those whose wound remained open
(t-test, P ¼ .026). A total of 104 patients were tested for
HbA1C, including 63 patients with a history of diabetes
mellitus (62 measured at screening or run-in, one at end of
treatment) and 41 patients with no history of diabetes.
Three patients with a positive history were not tested. The
HbA1C levels were similar among patients with a history
of diabetes, whether treated with vehicle (50.27 mmol/
mol 6 8.57) or with cells (54.10 mmol/mol 6 15.87; P ¼
.224). There was no evidence of a signiﬁcant effect of the
HbA1C level on ulcer healing, either in the control or the
cell-treated groups.
Most patients reported perceiving a monoﬁlament
probe (87.7%, 200/228). Those who lacked perception
were regarded as having peripheral neuropathy. Among
104 patients for whom HbA1C values had been deter-
mined, those with peripheral neuropathy had signiﬁcantly
higher baseline HbA1C values than those who reported
feeling the monoﬁlament (57.49 mmol/mol 6 19.87 vs
44.63 mmol/mol 6 10.79; P ¼ .0105). There was no
signiﬁcant difference in the incidence of wound closure in
the presence of neuropathy, as 74.1% of those reporting
lack of sensation healed compared with 58.5% of those
with normal sensory perception (P ¼ .179).
Among patients treated with cells, BMI was signiﬁcantly
greater for those who healed (median, 34.0; range, 18.6-
63.0) than for those who did not heal (median, 29.4;
range, 18.4-65.5; P ¼.007). Among patients treated with
Table I. Patient demographics
Category
Total
(N ¼ 228)
Vehicle
(n ¼ 50)
Low dose, cells High dose, cells
Biweekly
(n ¼ 46)
Weekly
(n ¼ 43)
Biweekly
(n ¼ 44)
Weekly
(n ¼ 45)
Age, years 62.0 (61.6 6 15.2)
[22-94]
59.5 (62.1 6 14.1)
[33-91]
63.0 (61.7 6 15.7)
[24-88]
64.0 (62.6 6 15.4)
[28-93]
61.0 (59.8 6 15.0)
[22-89]
62.0 (61.8 6 16.1)
[24-94]
Male 135 (59.2%) 33 (66.0%) 26 (56.5%) 29(67.4%) 22 (50.0%) 25 (55.6%)
Female 93 (40.8%) 17 (34.0%) 20 (43.5%) 14 (32.6%) 22 (50.0%) 20 (44.4%)
White 164 (71.9%) 37 (74.0%) 34 (74.0%) 30 (69.8%) 30 (68.2%) 33 (73.3%)
Black 48 (21.1%) 9 (18.0%) 10 (21.7%) 9 (20.9%) 12 (27.3%) 8 (17.8%)
Other 16 (7.0%) 4 (8.0%) 2 (4.3%) 4 (9.3%) 2 (4.5%) 4 (8.9%)
Area, cm2 4.9 (5.5 6 3.1)
[1.1-19.2]a
4.7 (5.4 6 3.1)
[1.1-14.7]
5.0 (5.1 6 2.5)
[1.1-12.1]
4.6 (5.4 6 2.7)
[1.5-11.9]
5.2 (6.0 6 3.4)
[2.0-17.4]
4.7 (5.9 6 3.6)
[1.9-19.2]
Duration, weeks 24.0 (33.5 6 1.9)
[6-104]
17.7 (29.5 6 24.6)
[6-102]
22.0 (34.8 6 29.1)
[6-104]
23.9 (36.1 6 31.3)
[6-104]
25.0 (34.1 6 29.2)
[6-100]
24.0 (33.8 6 27.0)
[6-104]
Weight, kg 100 (103 6 34) 102 (108 6 39) 93 (96 6 26) 100 (102 6 34) 95 (101 6 29) 104 (107 6 38)
Ankle 103 (45.2%) 23 (46.0%) 20 (43.5%) 24 (55.8%) 18 (40.9%) 18 (40.0%)
Lower calf 110 (48.2%) 26 (52.0%) 22 (47.8%) 17 (39.5%) 21 (47.7%) 24 (53.3%)
Upper calf 15 (6.6%) 1 (2.0%) 4 (8.7%) 2 (4.7%) 5 (11.4%) 3 (6.7%)
Diabetes 66 (28.9%) 19 (38.0%) 14 (30.4%) 10 (23.2%) 15 (34.1%) 8 (17.8%)
Neuropathy 27 (11.8%) 7 (14.0%) 6 (13.0%) 4 (9.3%) 6 (13.6%) 4 (8.9%)
Values given as median, (mean 6 SD), and [range]. No statistically signiﬁcant differences (imbalances) were found between groups for any variable listed.
aBaseline values at the end of a 2-week run-in period, during which time wounds may have increased (debridement or deterioration) or decreased (healing) in
size since screening.
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those who healed (median, 33.0; range, 23.1-82.5) than
for thosewho did not heal (median, 30.3; range, 16.7-62.0).
Slightly more than one-half of all patients (55%) under-
went debridement at the baseline visit. There were no
statistically signiﬁcant differences between groups in the
proportion of patients having wound debridement at any
visit. Patients for whom no debridement was recorded
during the study had outcomes indistinguishable from
those who had debridement performed routinely. For
example, 43% (9/21) of vehicle-treated patients and 72%
(48/67) of cell-treated patients with no debridement at
either of the ﬁrst two run-in visits achieved wound closure,
compared with 48% (14/29) and 60% (66/110), respec-
tively, having undergone debridement at either or both
of the ﬁrst two visits. Based on analysis of debridements
performed after screening, during run-in, and during the
treatment phase, comparing those who healed to those
who did not heal, no relationship between debridement
and healing could be found for either vehicle-treated or
cell-treated patients. Overall, ankle goniometry showed
no strong correlations with outcome.
Wound bacteriology. All 228 patients were free of
clinically evident wound infection at the time of randomiza-
tion. Only 227 patients are analyzed here, as one patient
died prior to ﬁrst treatment. Quantitative bacteriology
assessment of baseline wound bed tissue yielded positive
cultures in 192/221 patients (87%), with biopsies not per-
formed in six patients. Most (110) positive cultures yielded
a single species, with 60 each yielding two, 18 yielding three,
four yielding four different species, whereas 29 cultures
were negative. Among patients with negative cultures,
40% healed with vehicle treatment (2/5) compared with
67% with cell treatment (16/24) (P¼ .339), for 62% overallhealing. The positive cultures identiﬁed 37 species and 20
genera. No culture yielded 1  106 or greater cfu/g. Total
quantities of bacteria were similar among patients whose
wounds healed (median, 3.5  104 cfu/g; mean, 9.5 6
11.5  104 cfu/g) and those whose wounds remained
open (median, 3.0  104 cfu/g; mean, 8.3 6 10.3  104
cfu/g). Bacteria associated with a lower than average
proportion healed (<60%) were tabulated according to
treatment group, giving 71 patients with 92 positive
cultures (Table II). We termed these bacteria “inhibitory
bacteria,” which were all facultative anaerobes, with the
exception of Pseudomonas species. Thirty-three percent of
patients (59/177) in the cell-treated groups harbored one
or more of these bacteria compared with 24% in the vehicle-
treated group (12/50). The concentrations of bacterial
species, inhibitory or noninhibitory, were not different
between the cell-treated and vehicle control groups.
To assess the effect of bacteriology on wound healing,
the number of those bacteria with $1  104 cfu/g was
calculated, respectively, for both the inhibitory and nonin-
hibitory bacterial families as identiﬁed in Table II and was
used as the “bioburden index” of the corresponding
bacteria family. A regression model, including treatment
(cells vs vehicle) and both the inhibitory and noninhibitory
bioburden indices as the predictors, was performed on
wound healing, using logistic analysis. The same regression
analysis was further performed, respectively, for cell-treated
subjects and vehicle-treated subjects. A signiﬁcant, positive
effect on wound healing was seen for treatment (slope,
0.8721; P ¼ .0096), whereas a signiﬁcant, overall negative
effect on wound healing was seen for inhibitory bioburden
index (slope, 0.6803; P ¼ .0021). The effect of noninhi-
bitory bioburden index on wound healing was not statisti-
cally signiﬁcant (slope, 0.3499; P ¼ .1625).
Table II. Proportion of wounds closed in the presence of inhibitory bacteria
Having (þ) culture for All patients (n ¼ 228) Vehicle (n ¼ 50) Cells (n ¼ 177)
Noninhibitory
Acinetobacter spp. $1  104 75% (3/4) 0% (0/ 1) 100% (3/3)
Serratia spp. $1  104 86% (6/7) 67% (2/3) 100% (4/4)
Providencia spp. $1  104 50% (2/4) 0% (0/1) 67% (2/3)
Staphylococcus spp. $1  104 62% (60/97) 50% (10/20) 65% (50/77)
Staphylococcus aureus $1  104 60% (53/88) 50% (10/20) 63% (43/68)
Proteus spp. $1  104 67% (4/6) 100% (1/1) 60% (3/5)
Inhibitory
Strept. beta-hemolytic $1  103 52% (11/21) 0% (0/2) 58% (11/19)
Morganella morganii $1  104 50% (3/6) d 50% (3/6)
Pseudomonas spp. $1  104 47% (7/15) 33% (1/3) 50% (6/12)
Enterococcus spp. $1  104 39% (7/18) 0% (0/1) 41% (7/17)
Klebsiella spp. $1  104 38% (6/16) 25% (1/4) 42% (5/12)
Enterobacter spp. $1  104 36% (4/11) 0% (0/2) 44% (4/9)
Escherichia coli $1  104 20% (1/5) 0% (0/3) 50% (1/2)
Any below the dashed linea 8% (1/12) 49% (29/59)
aThe denominators reﬂect several cases of individual patients with more than one bacterial species.
Fig. Woundbioburdenandduration.Boxandwhiskerplot showing
the median, 25th percentile, 75th percentile (box), and 95% conﬁ-
dence intervals (whiskers) of wound durations by quantities of certain
bacterial species recovered from a punch biopsy specimen taken at
the screening visit. Bioburden levels were signiﬁcantly greater in
wounds of longer duration (P < .001). cfu, Colony forming units.
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effect on wound healing was seen for the inhibitory
bioburden index (slope, 0.6199; P ¼ .0086). For the
vehicle-treated subjects, a more negative but, likely because
of sample size, not statistically signiﬁcant effect on wound
healing was seen for the inhibitory bioburden index (slope,
1.1478; P ¼ .0811). Although the association between
measured bacterial concentration and healing did not differ
signiﬁcantly between the groups, an association existed
between failing to heal and inhibitory bioburden, as
vehicle-treated wounds harboring inhibitory bacteria were
more likely to remain open at the end of treatment (92%)
compared with cell-treated wounds (51%) (odds ratio,
10.63; 95% conﬁdence interval, 1.29-87.69; P ¼ .0096).
Wound bioburden was associated with increasing wound
duration (Fig), with wounds harboring inhibitory species
having signiﬁcantly greater duration compared with other
wounds (P < .001, Mann-Whitney). A summary of the
inﬂuence of variables tested is presented in Table III.
DISCUSSION
In the setting of controlled trials, the use of infection
control, debridement as necessary, wound moisture
control, and application of a high-compression bandage
system results in VLU closure in 30%-75% of patients
over a 12- to 24-week time period.1,13-16 In line with
our ﬁndings, a number of published studies noted that
larger wounds, wounds of greater duration, and wounds
below the ankle have a reduced probability of healing. Phil-
lips reported that wound size and duration were important
variables, whereas sex, race, age, skin condition, and
clinically evident infection had no prognostic value.17
Using multivariate analysis of more than 20,000 patients,
Margolis found age, sex, number of wounds, and wound
depth to be minor contributors, whereas wound size and
duration were major contributors to a risk of not healing.11
Patients with persistent wounds may be recruited into
clinical trials of potential new therapies on the assumptionthat variables, which contributed to initial failure, will
continue to limit responses in the standard care control
group, while yielding to the intervention.11 Thus, for
example, wounds of relatively small size may be enrolled
on the presumption that something other than size resulted
in failure to heal with standard care alone. Despite this,
VLU interventional trials typically exclude patients who
have conditions assumed to be barriers to healing, such
as poorly controlled diabetes. The potential beneﬁt of the
intervention may, thus, be underestimated or missed
entirely, and generalizeability of positive results becomes
limited by each additional exclusion criterion.18
Table III. Inﬂuence of tested variables on complete
healing
Category
More likely to
heal when
P value
Cell
group
Vehicle
group
Age No effect .748 .922
Sex No effect .393 .891
Race No effect .142 .203
HbA1C No effect .300 .360
MF sensation No effect .202 .689
BMI Greater .007 .206
Location Leg .011 .570
Area Smaller .026 .444
Duration Younger .012 .004
Quant. bact. #1  104 select species .002 <.001
BMI, Body mass index.
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unaffected by age or sex. Area and location inﬂuenced heal-
ing in the control group, but the effect did not reach signif-
icance. We found that certain variables, often presumed to
impair healing (history of diabetes mellitus, elevated
HbA1C level, peripheral neuropathy, decreased serum
prealbumin), did not inﬂuence outcomes. Patients with
high BMI did well in this study, suggesting that the condi-
tions of the study and perhaps cell therapy in particular,
overcame this presumed impediment to healing. No
evidence was found to suggest that wound bed sharp
debridement performed routinely inﬂuenced healing
regardless of clinical indication.19
An unexpected ﬁnding was that modest quantities of
certain bacteria correlated with poor response to treatment,
and to a greater degree, in patients receiving vehicle
compared with patients treated with cells. Although the
reason for these ﬁndings is not entirely clear, the identiﬁed
bacterial species are likely to elaborate virulence factors
and/or inﬂuence host inﬂammatory responses in a manner
detrimental to healing. To the extent that bacterial counts
tended to increase with increasing wound duration, it is
possible that colonization is secondary to chronicity rather
than causally related. Our study did not assess whether
bacterial counts were reduced, or species eliminated, prior
to the initiation of healing, and thus, we cannot conclude
with certainty that these species reinforce unresponsiveness.
In fact, healing rates were lower with standard care than
with cells even among patients with no bacteria recovered
from the wound bed. We did not evaluate bioﬁlms.
As noted, it is possible that wound duration, and perhaps
wound area, are surrogates for impediments to healing that
may (eg, extent of venous disease)20 or may not (eg, bacte-
rial colonization with certain species)21 be routinely
measured. Additional potential impediments not routinely
measured include local innate immune responses, which
are inappropriately active22 or inactive,23 ﬁbroblast senes-
cence induced by oxidative stress,24 or wound bed ﬁbrosis.25
Measurement of such variables is far from practical in a clin-
ical setting, as local tissue immune responses, bioﬁlm assays,and ﬁbroblast senescence are not readily assayable. Still,
greater duration of a wound at presentation may suggest
a need to rule out arterial or vasculitic components,4 or to
initiate earlier aggressive therapy rather than to wait for
failure of standard care therapies.
Our ﬁndings are in agreement with a recent compre-
hensive cohort design study in a population of 250,000.4
Among 113 patients with 138 wounded limbs, large ulcer
size, age > 65, diabetes, varicose eczema, and atrophie
blanche were not associated with delayed closure, whereas
duration greater than 18 months, wheelchair or bedbound
status, poor ankle mobility, equinus deformity, evidence of
DVT, and superﬁcial thrombophlebitis as well as the pres-
ence of lipodermatosclerosis were associated with delayed
healing. Bacterial burden showed interesting trends;
presence of clinical cellulitis, of Staphylococcus aureus or
b-Streptococcus were associated with delayed healing. This
association, however, was not statistically signiﬁcant.
Several limitations affect interpretation of our results.
The trial was not designed to prospectively test any of
the observed correlations, thus, causal conclusions should
not be drawn. Wounds were limited in size to 2-12 cm2,
which does not account for the small proportion of VLU
that are larger than 12 cm2.9 Combining all cell-treated
patients together creates an imbalance in statistical power
between the treated and control groups, raising caution
in the interpretation of P values. Some variables were
measured with greater precision than others. For example,
wound area was determined using digital imaging, whereas
in some cases, wound duration was based on patient recall.
In summary, cell therapy was able to overcome one or
more impediments to healing in the population studied.
Our ﬁndings imply that future interventional trials may
beneﬁt from stratiﬁed randomization on wound duration
and should avoid excluding subjects for the presence of
variables not known to inﬂuence outcome.AUTHOR CONTRIBUTIONS
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